|
SP-01A is an antiviral adjuvant indicated in the treatment of HIV-infected individuals. In Phase II clinical trials, SP-01A proved itself to be highly effective in significantly reducing viral load and improving quality of life without compromising the health or safety of HIV-infected patients.
|
